The connection between the shingles vaccine and dementia risk just became one of the most important health stories of 2026. A study of more than 500,000 older adults, published in the prestigious Annals of Internal Medicine, found that getting vaccinated against shingles was associated with a 24% lower risk of developing dementia over four years. Dementia is one of the most feared conditions of aging, and a vaccine already available at your local pharmacy may meaningfully lower your risk.
Here’s exactly what the study found, how the science explains it, and what it means for you.
1. The 2026 Study: What 500,000 People Tell Us About the Shingles Vaccine and Dementia Risk
Researchers from Brown University School of Public Health and the University of Delaware used a method called target trial emulation, essentially designing the analysis to mimic a randomized trial as closely as possible using real-world data, drawing on linked Medicare claims and electronic health records from more than 5,500 skilled nursing facilities.
The population: more than 500,000 adults aged 66 and older who had been admitted to a skilled nursing facility for short- or long-term care between 2017 and 2022. Researchers compared those who received at least one dose of the recombinant zoster vaccine (RZV, sold as Shingrix) within 12 months of admission against those who did not.
The headline finding: vaccinated individuals had a 24% lower relative risk of developing dementia over the following four years, translating to roughly a 6-percentage-point absolute risk reduction compared with unvaccinated individuals.
Why this population matters: skilled nursing facility residents already carry elevated baseline risk for both shingles and dementia, due to age, frailty, and immune changes common in this group. A protective signal this large, in a population this vulnerable, is part of what makes the finding so notable to researchers.
As lead author Kaley Hayes, PharmD, PhD, of Brown University’s School of Public Health, put it: “It’s really amazing to see that something that’s supposed to prevent a physical ailment can also help keep our brain healthy too.”
2. How the Shingles Vaccine and Dementia Risk Are Biologically Connected
Researchers have proposed several mechanisms, and it’s worth understanding that none of them are fully settled science yet, they’re the leading hypotheses, with growing but still incomplete evidence.
Mechanism 1: The Virus Itself May Affect the Brain. The varicella-zoster virus (VZV), the same virus that causes chickenpox and, later in life, shingles, doesn’t stay confined to the skin. It travels along nerve pathways and has been found capable of affecting the central nervous system. Researchers believe active viral reactivation may trigger neuroinflammation, a process increasingly understood to play a role in Alzheimer’s disease pathology.
Mechanism 2: The Adjuvant Itself May Matter. A separate study compared the AS01-adjuvanted shingles vaccine (Shingrix) against the AS01-adjuvanted RSV vaccine (Arexvy) and found no meaningful difference between them in dementia-risk reduction, a finding that suggests the AS01 adjuvant component itself, which helps stimulate a stronger immune response, may play a direct role in lowering dementia risk somewhat independent of which specific virus the vaccine targets. This is an active area of research, not a settled mechanism.
Mechanism 3: Preventing the Inflammatory Cascade of a Shingles Outbreak. A shingles outbreak itself triggers a significant systemic inflammatory response. In older adults with already-vulnerable brains, researchers theorize this inflammatory surge could accelerate processes linked to amyloid plaque accumulation and tau protein changes, two hallmarks of Alzheimer’s disease. Preventing the shingles outbreak in the first place would remove this inflammatory trigger entirely.
None of these mechanisms has been definitively proven as the explanation, and they aren’t mutually exclusive. It’s plausible more than one is contributing simultaneously.
3. This Isn’t the First Study — The Evidence Is Stacking Up
What makes this 2026 finding particularly compelling is that it’s the latest in a growing line of independent research pointing in the same direction, using different methods, different populations, and even different vaccine formulations:
2025 — Stanford/Cardiff “natural experiment” in Wales (published in Nature, April 2025). Researchers led by Stanford’s Pascal Geldsetzer took advantage of an unusual quirk in how Wales rolled out its shingles vaccination program: eligibility was determined by exact date of birth, creating two nearly identical comparison groups based on essentially random chance. This design is considered one of the strongest available for inferring causation from observational data. The result: people who received the (older, live-attenuated) shingles vaccine were about 20% less likely to develop dementia over the following seven years than those who didn’t.
2025 — AS01 adjuvant comparison study. As described above, this research compared the AS01-adjuvanted shingles vaccine against the AS01-adjuvanted RSV vaccine and found both were associated with reduced dementia risk over an 18-month window, with no significant difference between them, pointing toward the adjuvant itself as a contributing factor.
2026 — Brown University / Annals of Internal Medicine (this study). 500,000+ people, Shingrix specifically, 24% relative risk reduction over four years.
Three independent research teams, three different study designs, multiple countries and vaccine formulations, and all pointing in the same direction. That pattern matters enormously in science: a single study can be a fluke; convergent findings across very different methodologies are much harder to dismiss.
Commenting on the broader body of evidence (prior to this specific 2026 study), Harvard T.H. Chan School of Public Health’s Alberto Ascherio, professor of epidemiology and nutrition, called the findings “promising,” noting that the research suggests “something can be done to stave off dementia, for which there are few effective treatments.” He also offered an important caveat: “Obviously, the [shingles] vaccine was not designed or optimized to prevent dementia, so this is sort of an incidental finding. In some ways, we are being lucky.”
4. Who Should Get the Shingles Vaccine (And Who Shouldn’t)
Should get Shingrix, per CDC guidance:
- Adults 50 years and older, regardless of whether they recall having had shingles before, and regardless of whether they previously received the older Zostavax vaccine
- Adults 19 and older who are immunocompromised due to disease or therapy (including chemotherapy patients, people living with HIV, and organ transplant recipients)
- Anyone who previously received Zostavax (no longer available in the U.S. as of 2020; Shingrix provides substantially stronger and longer-lasting protection)
Should wait or consult a doctor first:
- Anyone with a history of a severe allergic reaction (such as anaphylaxis) to any component of the vaccine or to a previous Shingrix dose, this is a true contraindication, not just a precaution
- People currently experiencing an active shingles outbreak, vaccination should be delayed until the rash has crusted and symptoms have resolved
- People with a moderate or severe acute illness, with or without fever wait until recovery
- Pregnant individuals, there’s currently no official ACIP recommendation for Shingrix use during pregnancy specifically, so providers generally suggest waiting until after pregnancy out of caution, even though there’s no known specific risk identified
A safety note worth knowing about: postmarketing surveillance has identified an increased risk of Guillain-Barré syndrome (a rare condition causing temporary muscle weakness) following Shingrix vaccination. This is a disclosed, monitored safety signal, not a reason to avoid the vaccine for most people, but something worth being aware of and discussing with your doctor if you have a personal or family history of this or similar conditions.
For details on depression, anxiety, and other brain-health topics this connects to, see our All Conditions health guide.
5. How Effective Is the Shingles Vaccine? The Full Numbers
| Population | Shingrix Effectiveness Against Shingles |
| Adults 50–69, healthy immune system | 97% |
| Adults 70+, healthy immune system | 91% |
| Adults with weakened immune systems | 68–91% (varies by condition) |
| Prevention of postherpetic neuralgia (age 50+) | 91% |
| Immunity duration | Strong protection confirmed for at least 7 years |
Practical details:
- Shingrix is given as a two-dose series, with the second dose administered 2–6 months after the first (1–2 months for people who are or will be immunocompromised and would benefit from a shorter interval)
- Available at most pharmacies without a prescription required in most states
- Medicare Part D covers Shingrix at $0 out-of-pocket for nearly all beneficiaries; most private insurance plans cover it as well, though you should confirm with your specific plan
- Tip: schedule your second dose appointment at the same time you get your first, so you don’t have to remember to book it later
6. What to Expect When Getting Shingrix — Side Effects and Timeline
Shingrix produces a deliberately strong immune response, which is part of why it’s so effective, and also why temporary side effects are common.
Common side effects (most resolve within 2–3 days): a sore arm with mild-to-moderate pain, redness and swelling at the injection site, fatigue, muscle pain, headache, shivering, fever, stomach pain, and nausea. These side effects were more common in younger vaccine recipients than older ones in clinical trials.
Why this is actually a reasonable sign: these temporary symptoms reflect your immune system mounting a strong response, generally a sign the vaccine is doing what it’s designed to do, not a sign something is wrong. Side effects may temporarily limit your normal activities for a day or two, so some people prefer to schedule their appointment before a day off.
You should still get your second dose even if you experienced these side effects after your first, discontinuing partway through means you won’t get full protection.
What to tell your doctor before vaccination: any history of severe allergic reactions to vaccines, current pregnancy or plans to become pregnant, any immunocompromising conditions or treatments, and any history of Guillain-Barré syndrome.
7. Other Proven Ways to Lower Your Dementia Risk
The shingles vaccine is one promising piece of a much bigger picture. Other approaches with strong supporting evidence include:
- Regular physical activity, both aerobic exercise and strength training have well-established links to better cognitive outcomes with age
- Diet quality, eating patterns like the Mediterranean diet and broader plant-based eating approaches are associated with better long-term brain health outcomes in observational research
- Managing blood pressure, blood sugar, and cholesterol, cardiovascular health and brain health are deeply intertwined; what’s good for your heart tends to be good for your brain
- Quality sleep, consistently getting 7–9 hours supports the brain’s overnight clearance processes; our guide on magnesium’s role in sleep support covers one evidence-backed approach if sleep has been a struggle
- Social connection and cognitive stimulation, both are consistently associated with lower dementia risk in long-term cohort studies
- Staying current on other emerging research, our coverage of intermittent fasting’s effects on brain health and probiotics as an emerging mental health intervention both explore other angles on the gut-brain and lifestyle-brain connection
- Being thoughtful about other supplements that affect brain health, for instance, our coverage of glucosamine’s potential Alzheimer’s risk connection is worth reading if you take that supplement regularly
For more general preventive health strategies, our Alternative Health hub covers additional evidence-based approaches.
8. Study Limitations — What We Still Don’t Know
This is essential context for understanding how much weight to put on this finding.
This study does not prove cause and effect. Despite the rigorous target trial emulation design, this remains an observational study. Randomized controlled trials, where researchers actually assign who gets the vaccine and who doesn’t, are still needed to establish more definitive causal evidence and to clarify the underlying mechanism.
The population studied is specific. Skilled nursing facility residents may not represent all older adults broadly, including healthier, community-dwelling seniors who make up the majority of the 50+ population.
Funding disclosure. The study authors disclosed funding from GlaxoSmithKline, which manufactures Shingrix, while explicitly noting that the company had no control over the study design, analysis, or the decision to publish results. This is a standard and appropriate disclosure, and it’s worth knowing about as you weigh the source of the research.
“Healthy vaccine bias” is a known limitation in this research area. People who choose to get vaccinated tend, on average, to engage in other health-protective behaviors too, though researchers attempted to statistically adjust for a wide range of demographic and health factors, and the protective association held up after those adjustments, this kind of selection effect can never be fully eliminated in observational research.
The path forward: ongoing and planned randomized controlled trials, including efforts already underway in Wales building on the Stanford/Cardiff natural experiment, aim to provide the stronger causal evidence this finding deserves.
9. FAQs About Shingles Vaccine and Dementia Risk
Does the shingles vaccine really reduce dementia risk? A 2026 study of over 500,000 older adults found that getting the Shingrix shingles vaccine was associated with a 24% lower relative risk of developing dementia over four years. This finding adds to a growing, independently-replicated body of evidence pointing in the same direction, though it’s observational, not yet proven through a randomized controlled trial.
Can shingles cause dementia? Researchers haven’t established that having shingles directly causes dementia, but there’s a plausible biological pathway: the virus that causes shingles can affect the nervous system and trigger inflammation that may contribute to the kind of brain changes seen in Alzheimer’s disease. Preventing shingles through vaccination is the more actionable takeaway here.
Which shingles vaccine protects against dementia — Shingrix or Zostavax? Both vaccine types have shown associations with reduced dementia risk in different studies, Shingrix in the new 2026 Brown University study, and the older live-attenuated vaccine (similar to Zostavax) in the 2025 Wales natural experiment. Zostavax is no longer available in the U.S., so Shingrix is the relevant option for anyone getting vaccinated now.
How many doses of Shingrix do I need? Two doses, given 2–6 months apart for most adults (or 1–2 months apart for people who are or will be immunocompromised and would benefit from finishing the series sooner).
Is it too late to get the shingles vaccine at 70 or 80? No. In fact, the population studied in the 2026 Brown University research had a mean age of 79, and the vaccine remains recommended and effective for adults well into their 70s, 80s, and beyond, including those with weakened immune systems.
Does the shingles vaccine work if I’ve already had shingles? Yes. The CDC recommends Shingrix for adults 50+ regardless of whether they’ve previously had a shingles episode, since you can get shingles more than once.
How much does Shingrix cost and does insurance cover it? Shingrix is $0 out-of-pocket for almost everyone with Medicare Part D coverage and for the vast majority of people with private insurance. Check with your specific plan to confirm your coverage.
Can I get Shingrix and the flu shot at the same time? Yes. Shingrix can be administered at the same time as other vaccines, including flu shots and COVID-19 vaccines, typically at different injection sites.
Conclusion
The connection between the shingles vaccine and dementia risk is one of the most genuinely hopeful findings in dementia research in years, not because it’s proven beyond doubt, but because it points to something concrete and immediately actionable in a field that has had very few wins. This is an observational study, not a randomized trial, and the researchers themselves are clear that more research is needed to establish causation. But the vaccine itself is FDA-approved, widely available, well-studied for its primary purpose, and recommended for most adults 50 and older regardless of this dementia research. If you are due for Shingrix, this is one more reason to talk to your doctor about scheduling it.
Continue exploring: see how other supplements may affect Alzheimer’s risk, or learn about the gut-brain connection’s role in cognitive and mental health in our companion guide.
